Pharmafile Logo

Solymbic

Amgen appoints Jonathan Graham general counsel and secretary

He will succeed David Scott who is retiring

- PMLiVE

Flurry of FDA guidance firms up biosimilar policy

The American regulator has released new biosimilar Q&A document

- PMLiVE

AbbVie remains top of immunology sales

But the threat of biosimilars once again threatens to shake up the leader board

- PMLiVE

Novartis biosimilar blocked by US court

Swiss firm’s Neupogen copy has its injunction upheld at appeal

- PMLiVE

Harvoni sales rocket in first quarter

Gilead’s new hepatitis C pill generates stellar revenue

- PMLiVE

FDA panel backs Amgen’s T-Vec for melanoma

Approved by a panel of 22 to one despite questions on its impact on survival

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo backed as melanoma therapy in EU

First checkpoint inhibitor to be recommended for approval in the region

Roche Basel Switzerland

Roche maintains top place in biologic sales

But the looming threat of biosimilars is set to shake up the market

- PMLiVE

Amgen starts shipping Corlaner in US

Firm also reports healthy financial growth in the first quarter

- PMLiVE

FDA clears Amgen’s Corlaner for heart failure

It is the firm’s first cardiovascular product to gain approval

- PMLiVE

Top biotech firms saw sales jump in 2014

But rate of growth slowing from the past five years according to new analysis

- PMLiVE

Amgen gets EU nod for wider use of Vectibix

US biotech’s cancer therapy can now be used in a first-line setting

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links